AUTH/2778/7/15: Merz v Ipsen – Dysport leavepieces and dose-ratio comparisons | PMCPA Case

📊

Key facts

⌄

Case number	AUTH/2778/7/15
Parties	Merz Pharma UK Limited v Ipsen Limited
Product	Dysport (botulinum toxin type A)
Materials	Two leavepieces: “Comparison of SPC Doses” (UK/DYS08687(1)); “Botulinum Toxins – The Ratio Challenge” (UK/DYS08686(1))
Main issue	Implied recommended dose ratios derived from indirect SPC comparisons; maximum-dose presentation lacking SPC nuance/safety context; systematic review summary out of date and misleading
Complaint received	07 July 2015
Case completed	03 September 2015
Applicable Code year	2015
Appeal	No appeal
No breach clauses	7.2, 7.3, 7.4
Breach clauses	7.2 (x2,), 7.3 (x2), 7.4, 7.10
Sanctions	Undertaking received; Additional sanctions: Not stated

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

Merz complained about two Ipsen leavepieces promoting Dysport (botulinum toxin type A) that discussed dose ratios versus other BoNT-A products (including Xeomin and Botox).
Leavepiece 1 (ref UK/DYS08687(1)) tabulated SPC dosing for Dysport, Botox and Xeomin and included a “Dose ratios” column (eg Dysport:Xeomin ratios by indication, including maximum-dose ratios such as 3.3:1 for cervical dystonia).
Leavepiece 2 (ref UK/DYS08686(1), dated January 2014) summarised a systematic review/meta-analysis conducted in February 2012 and stated on the front page that “no studies compared Dysport and Xeomin”.
Ipsen said the materials were part of a “Dispelling the Myth” campaign (launched April 2013) intended to counter tender-driven proposals for a blanket 4:1 switch ratio and to reinforce that toxin units are not interchangeable and that no single ratio can be applied across indications/health economies.
Merz alleged the SPC-based ratios were misleading indirect comparisons and that the systematic-review leavepiece was incomplete/out of date (not reflecting later evidence and a September 2014 updated review).
The Panel also considered the combined use of the two leavepieces, given the sales briefing suggested SPCs were the “only comparison and guidance” and that there were “no publications comparing Dysport and Xeomin” (which became out of date).

⚖️

⌄

No breach was ruled for Clauses 7.2, 7.3 and 7.4 in relation to the allegation that the SPC leavepiece compared registration studies per se.
Breach rulings were made because the SPC leavepiece appeared to present unequivocal, recommended dose ratios per indication based on indirect SPC comparisons (not head-to-head studies) and because maximum-dose information was presented simplistically without reflecting SPC nuance/safety context.
Breach rulings were made because the systematic-review leavepiece (January 2014) was not based on an up-to-date evaluation of all relevant data (it did not reflect the September 2014 meta-analysis and later Dysport:Xeomin evidence), making the presentation misleading.
The Panel considered the two leavepieces “inextricably linked” and applied its breach findings to their combined use.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access